Delivery Order SPE2DR25D3303-SPE2DR26F61E7
Award Date 11/14/25
Potential Completion Date 11/17/25
Potential Value $1.2K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a delivery order valued at $2,265.90 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mls on September 4, 2025, with an ultimate completion date of September 5, 2025. This competitively awarded, firm fixed-price delivery order was placed with no set-aside designation and is being performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used biologic immunosuppressant medication indicated for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of HUMIRA Pen 40 mg/0.8 mL with a ceiling value of $1,132.95. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The order is set to be completed by October 24, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used...
- The Defense Logistics Agency awarded a delivery order valued at $3,776.50 to AmerisourceBergen Drug Corp for HUMIRA Pen 40 mg/0.8 mL on July 9, 2025, with completion scheduled for July 10, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. HUMIRA (adalimumab) is a widely-used immunosuppressant biologic medication prescribed for inflammatory conditions...
- The Defense Logistics Agency awarded a delivery order valued at $1,227.99 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on November 7, 2025, with completion scheduled for November 10, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. HUMIRA is a biologic immunosuppressant medication used to treat various inflammatory and autoimmune conditions,...
- The Defense Logistics Agency awarded a $7,022.45 delivery order to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) CF Pen 40 mg/0.4 mL on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-competitive delivery order is issued under a firm fixed-price arrangement and represents a single pharmaceutical supply transaction sourced from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania. HUMIRA is a widely prescribed biologic immunosuppressant used to...
- The Defense Logistics Agency awarded a delivery order valued at $5,497.68 to AmerisourceBergen Drug Corp for HUMIRA (Adalimumab) Pen 40 mg/0.4 mL on August 19, 2025, with completion targeted for August 20, 2025. This firm fixed-price delivery order represents a non-set-aside competitive procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a widely-used biologic immunosuppressant medication prescribed for various autoimmune conditions including...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 30, 2025, for the supply of HUMIRA (adalimumab) pen 40 mg/0.4 mL injections, with a ceiling value of $1,591.92. This is a firm fixed price delivery order with an ultimate completion date of October 31, 2025, and represents a non-competitive set-aside award. The product will be performed and delivered from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HUMIRA is a...
- The Defense Logistics Agency awarded a delivery order valued at $10,518.78 to AmerisourceBergen Drug Corp for HUMIRA (adalimumab) Pen 40 mg/0.4 mL on November 3, 2025, with completion scheduled for November 4, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. HUMIRA is a leading biopharmaceutical product used to treat various autoimmune and inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $37,698.62 to AmerisourceBergen Drug Corp for the supply of HUMIRA (Adalimumab) Pen 40 mg/0.4 mL, a biologic pharmaceutical used to treat autoimmune conditions. This firm fixed-price delivery order was competitively awarded without set-aside designation and has an ultimate completion date of May 21, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,883.59 to AmerisourceBergen Drug Corp for HUMIRA (CF) Pen 40 mg/0.4 mls on August 21, 2025, with an ultimate completion date of August 22, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered from...